|Videos|May 9, 2022
Neratinib for Metastatic HER2+ Breast Cancer and Brain Metastases
Oncologists debate the use of neratinib for metastatic HER2+ breast cancer treatment in the context of the HER2CLIMB clinical trial data on tucatinib.
Advertisement
Episodes in this series
Advertisement
Related to this article
Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
2
Clinical Applications and the Future of Remote Endovascular Procedures
3
Building a Low-Dose Radiation Therapy Program for Benign Disease
4
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
5